![]() |
|
|
Vol. 53, Issue 3, 385-391, March 1998
Department of Pediatrics, Philipps University, D-35033 Marburg,
Germany (T.K., R.N.),
Faculty of Biology, University of Konstanz,
P. O. Box 5560, D-78434 Konstanz, Germany (V.U.),
Centre of
Pharmacology, Johann Wolfgang Goethe University, D-60590
Frankfurt, Germany (J.P.)
One of the challenges in the therapy with anti-inflammatory drugs is
the avoidance of gastrointestinal side effects, which may be achieved
by selective inhibition of cyclooxygenase (COX) -2. CGP 28238 is
reported with these characteristics inhibiting selectively the COX-2
activity at nanomolar concentrations. However, we report here on a
novel action of this compound uncovered during the application of
higher concentrations. In rat mesangial cells, CGP 28238 induced the
mRNA and the protein of COX-2 as well as those of inducible nitric
oxide synthase and soluble phospholipase A2. In the case of
COX-2, this stimulation had no effect on the production of COX-2
metabolites because of the effective blockade of the enzyme. In
contrast, the level of NO produced by the cells increased in a
concentration-dependent manner from 1.2 to 12.5 nmol of nitrite/3 × 105 cells. Furthermore, in combination with low doses of
IL-1 CGP 28238 superinduced the formation of nitrite. The observed
effects were independent of the inhibition of prostaglandin formation, as suggested by the failure of the potent COX inhibitor diclofenac to
cause similar effects. Furthermore, the activity and expression of
enzymes downstream of the COX step, such as prostacyclin synthase, were
unaffected by CGP 28238. The inductive action of CGP 28238 could be
blocked by inhibitors for tyrosine kinases and protein kinase A, such
as genistein and KT5720, respectively. The increase in intracellular
cAMP concentration in rat mesangial cells and the inhibition by CGP
28238 of phosphodiesterase 4 activity with an IC50 value of
23 µM gave a rationale to explain the underlying mechanisms for the induction of the inflammatory response genes COX-2,
soluble phospholipase A2 and inducible NO synthase in rat mesangial cells.
This article has been cited by other articles:
![]() |
R. Nasrallah and R. L. Hebert Prostacyclin signaling in the kidney: implications for health and disease Am J Physiol Renal Physiol, August 1, 2005; 289(2): F235 - F246. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Kiemer, M. D. Lehner, T. Hartung, and A. M. Vollmar Inhibition of Cyclooxygenase-2 by Natriuretic Peptides Endocrinology, March 1, 2002; 143(3): 846 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Siegle, T. Klein, M.-H. Zou, P. Fritz, and M. Kömhoff Distribution and Cellular Localization of Prostacyclin Synthase in Human Brain J. Histochem. Cytochem., May 1, 2000; 48(5): 631 - 642. [Abstract] [Full Text] |
||||
![]() |
C.-C. Chen, K.-T. Chiu, Y.-T. Sun, and W.-C. Chen Role of the Cyclic AMP-Protein Kinase A Pathway in Lipopolysaccharide-induced Nitric Oxide Synthase Expression in RAW 264.7 Macrophages. INVOLVEMENT OF CYCLOOXYGENASE-2 J. Biol. Chem., October 29, 1999; 274(44): 31559 - 31564. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kroll, S. Kunz, T. Klein, and L. R. Schwarz Effect of lindane and phenobarbital on cyclooxygenase-2 expression and prostanoid synthesis by Kupffer cells Carcinogenesis, August 1, 1999; 20(8): 1411 - 1416. [Abstract] [Full Text] [PDF] |
||||